F-1/A: Otsaw Limited Targets Nasdaq Listing with $20M IPO to Fuel Robotics Expansion Amidst Recurring Losses

Otsaw Limited, a Singapore-based autonomous mobile robot (AMR) and robotics solutions provider, is seeking to raise $20 million in an initial public offering on Nasdaq to fund its global expansion, production capacity, and R&D, despite a history of recurring net losses and auditor-expressed 'substantial doubt' about its ability to continue as a going concern.

Summary

• Otsaw Limited specializes in AI-enabled autonomous mobile robots (AMRs) and robotics solutions for security, disinfection, last-mile delivery, and healthcare facilities.
• The company reported revenues of US$5.3 million for FY2024 and US$5.1 million for FY2023, with net losses of US$6.5 million and US$6.7 million, respectively.
• For the six months ended October 31, 2024, revenues were US$1.8 million, a decrease from US$2.8 million in the prior comparable period, and net losses increased to US$3.3 million from US$2.9 million.
• Service and maintenance contracts are the primary revenue driver, accounting for approximately 79.3% of total revenues in FY2024 and 85.3% for the six months ended October 31, 2024.
• The company plans to offer 4,000,000 Class A Ordinary Shares in its initial public offering, with an expected price range of US$4.50 to US$5.50 per share, aiming for US$20 million in gross proceeds.
• Net proceeds from the offering, estimated at US$16.6 million, are allocated to acquisitions/joint ventures (20%), production capacity/inventory (32%), market expansion (10%), R&D (10%), working capital (11%), and loan repayment (17%).
• Otsaw operates with a dual-class share structure, where CEO Ling Ting Ming will retain approximately 63.6% of the total voting power post-offering.
• The company's auditors have expressed 'substantial doubt' about its ability to continue as a going concern due to recurring losses and a net working capital deficit of US$12.4 million as of October 31, 2024.
• Key products include the O-R3 security patrol AMR, Camello+ multi-purpose delivery/security AMR, TransCar healthcare intralogistics AGV (through a joint venture with Swisslog Healthcare), and UV-C disinfection systems (AirGuard, TreX, O-RX).
• Otsaw aims to expand its production capacity to 15 units per month by Q3 2025 and commercialize its next-generation Autonomous Navigation System (ANS) Version 3, 'Odyssey', for broader industry application.
• The company has established international distribution channels and partnerships in over 20 countries, with a focus on expanding its presence in the United States, Canada, the United Kingdom, Australia, and GCC countries.

Sentiment

Score: 3

Explanation: The company presents a compelling vision and operates in high-growth markets with innovative products and strategic partnerships. However, significant financial challenges, including recurring losses, negative cash flow, and a going concern warning from auditors, heavily weigh down the sentiment. The reliance on future capital raises and the unproven large-scale manufacturing capabilities add substantial risk, making the outlook highly speculative despite the positive market trends and technological advancements.

Positives

• Otsaw Limited is an innovator in advanced robotics autonomy technologies and next-generation AI, with cutting-edge robotics software development and manufacturing capabilities.
• The company has a diversified product portfolio addressing critical needs in security, disinfection, last-mile delivery, and healthcare facilities management.
• Proprietary core software technologies, including patented 3D SLAM, Sensor Fusion, Machine Perception, and AI/Machine Learning, provide a competitive advantage.
• The company has established international distribution channels, partnerships, and customer relationships in more than 20 countries over the past seven years.
• The joint venture with Swisslog Healthcare provides immediate customer base and market access to hospitals and healthcare facilities in Europe and Southeast Asia, regions with high barriers to entry.
• The RaaS (Robots as a Service) model offers a compelling value proposition to customers by lowering upfront costs and providing comprehensive support, accelerating market adoption.
• The company has a visionary, proven, and experienced management team, including founder and CEO Ling Ting Ming, with extensive industry expertise.
• Otsaw is an early-mover in facilities management AMR and robotics solutions, accumulating vast operational data to improve product performance, adaptability, and reliability.
• The planned expansion of production capacity to 15 units per month by Q3 2025 aims to achieve cost-efficient manufacturing and competitive pricing.
• The development of ANS Version 3, 'Odyssey', is expected to unlock industry-wide application and tremendous monetization opportunities by licensing software to third-party manufacturers.
• The company has secured a US$2 million contract with a public hospital in Singapore for TransCar AGVs, demonstrating significant customer wins.
• Otsaw has received multiple industry awards and certifications, including the Merlion Award, Singapore Security Industry Award, and ISO 9001:2015 certification, validating its innovation and quality.

Negatives

• The company has a history of recurring net losses, reporting US$6.5 million in FY2024 and US$6.7 million in FY2023, and US$3.3 million for the six months ended October 31, 2024.
• Auditors have expressed 'substantial doubt' about the company's ability to continue as a going concern due to continuing losses from operations and limited working capital.
• The company has consistently experienced negative cash flow from operating activities, with US$2.3 million in FY2024 and US$1.5 million for the six months ended October 31, 2024.
• Working capital deficit remains significant, at US$12.4 million as of October 31, 2024.
• Revenue for the six months ended October 31, 2024, decreased by 35.8% compared to the prior comparable period, primarily due to lower AGV deployment and sales transition.
• Sales of robots decreased by 48.9% for the six months ended October 31, 2024, due to phasing out of existing models and new models not yet being on sale.
• The company relies on a small number of key customers for a significant portion of its service and maintenance revenue, posing concentration risk.
• The RaaS revenue stream declined by 42.9% in FY2024 due to decreased demand for pandemic-driven solutions (O-RX, O-R2 leases) and customer preference for newer technology.
• The management team lacks experience in managing a U.S. public company, which could lead to challenges in regulatory compliance and investor relations.
• The dual-class share structure concentrates voting control with the CEO, potentially limiting the influence of public shareholders.
• The company has significant investments in R&D that may not achieve expected returns, and its ability to manufacture products on a large scale is unproven.
• Dependence on single, sole, or limited source suppliers for key components (e.g., Reis Robotics for TransCar until June 30, 2025) poses supply chain risks.
• The company has incurred increased finance costs due to higher interest rates on director loans, which provide funding for daily operations.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and limited working capital.
• Uncertainty in generating positive operating cash flow, requiring new financing in the future.
• Significant investments in research and development may not achieve expected returns or market acceptance for new products.
• Limited operating history makes it difficult to evaluate business viability and increases investment risk.
• Future capital needs may require additional equity or debt securities, leading to substantial dilution or significant debt service obligations.
• No experience maintaining or servicing products at a large scale, potentially leading to customer dissatisfaction or increased costs.
• Unproven ability to manufacture, assemble, and produce products on a large scale, risking delays and cost overruns.
• The commercial robotic market is in early stages of customer adoption, and large-scale application of autonomous robots in facilities management is unproven.
• Difficulty in accurately predicting demand for products and managing inventory effectively, leading to potential write-downs or shortages.
• Targeting large corporations with substantial negotiating power and competitive internal solutions may adversely affect sales.
• Dependence on a small number of key customers for a significant portion of revenue, with risk of contract non-renewal or loss.
• Difficulties in expanding operations into new regions or countries with no prior operating experience, facing economic, regulatory, and personnel challenges.
• Operating in a rapidly evolving and competitive industry, with risk of market share decline due to technological evolution or aggressive pricing by competitors.
• Dependence on the global supply chain and experienced constraints due to COVID-19, inflation, and geopolitical events, leading to increased costs and extended lead times.
• Reliance on single, sole, or limited source suppliers for critical components (e.g., Reis Robotics for TransCar) could cause production delays and revenue loss.
• Inability to build, maintain, or strengthen the Otsaw brand, or negative publicity, could adversely affect product acceptance and revenue.
• Limited experience in operating robots in a variety of environments, increasing the likelihood of collisions, liability, and negative publicity.
• Design flaws, unknown defects, errors, glitches, or malfunctions in products or software could result in recalls, claims, injuries, property damage, and safety concerns.
• Subject to stringent and changing data privacy and security laws, regulations, and standards across multiple jurisdictions, leading to compliance costs and potential liabilities.
• Cybersecurity risks to operations, IT infrastructure, software, and data, potentially resulting in unauthorized access, data loss, or reputational harm.
• Unauthorized access or control of AMR and robotics systems could lead to loss of confidence and harm the business.
• Significant portion of net sales through distributors, leading to risks related to their performance, compliance, and relationship termination.
• Potential acquisitions, joint ventures, or investments may negatively affect operating results, cause dilution, or increase debt.
• Failure to manage significant business and operational expansion effectively could materially and adversely affect prospects.
• Risks associated with strategic alliances, such as the joint venture with Swisslog Healthcare, including sharing proprietary information, non-performance by partners, and integration challenges.
• Swisslog Healthcare's right to require the company to purchase its equity interests in the Otsaw-Swisslog JV could adversely affect liquidity.
• Loss of key personnel or inability to attract and retain highly qualified personnel could harm the business.
• Developments in the social, political, regulatory, and economic environment in operating countries may have a material adverse impact.
• Global economic conditions could materially adversely impact demand for products and services.
• Risks associated with international operations, including unfavorable regulatory, political, tax, and labor conditions.
• Potential involvement in legal proceedings, which could be expensive, lengthy, and disruptive.
• Exposure to foreign exchange risk due to fluctuations in currency exchange rates.
• Imposition of trade barriers, escalation of trade disputes, and changes to trade policy could adversely affect business.
• Subject to anti-corruption, anti-bribery, anti-money laundering, and sanctions laws, with noncompliance leading to fines and penalties.
• Failure of internal controls over financial reporting could harm business and financial results.
• Environmental laws and regulations and unforeseen costs could negatively impact future earnings.
• Inability to obtain and maintain intellectual property protection, or being subject to intellectual property claims, could adversely affect the business.
• Use of other parties' software, including open source, could lead to inability to continuously use such software or intellectual property.
• As a controlled company, the company may choose to exempt itself from certain Nasdaq corporate governance requirements, affording less protection to public shareholders.
• Class A Ordinary Shares may be thinly traded, making it difficult to sell shares at or near ask prices.
• No prior public market for Class A Ordinary Shares, with potential for price decline below IPO price.
• Failure to satisfy or continue to satisfy Nasdaq listing requirements could lead to delisting.
• Nasdaq may apply additional and more stringent listing criteria due to small public offering and large insider holdings.
• The trading price of Class A Ordinary Shares may be volatile, resulting in substantial losses.
• Exercise of options or issue of awarded shares under the 2025 Share Incentive Plan may result in dilution.
• Lack of research coverage or unfavorable research by analysts could cause stock price decline.
• Short selling may drive down the market price of Class A Ordinary Shares.
• Broad discretion in the use of net proceeds from the public offering, which may not be used effectively.
• No expected dividends in the foreseeable future, requiring reliance on price appreciation for return on investment.
• Shares eligible for future sale may adversely affect the market price.
• Immediate and substantial dilution for new investors.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• As a Cayman Islands company, shareholder rights may be more limited than those of a U.S. company.
• Judgments obtained against the company by shareholders may not be enforceable in the Cayman Islands or Singapore.
• Cayman Islands economic substance requirements may affect business and operations.
• Reduced disclosure requirements as an emerging growth company may make Class A Ordinary Shares less attractive.
• As a foreign private issuer, disclosure obligations differ from U.S. domestic reporting companies, offering less protection to investors.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. investors.
• Uncertainty regarding classification as a Singapore tax resident.

Future Outlook

Otsaw Limited plans to continue significant investments in research and development to upgrade its products and core software technologies, specifically the Autonomous Navigation System (ANS) from Version 2 to Version 3, branded as 'Odyssey', with development expected to commence in 2026 and a target launch in 2028. The company intends to commercialize Odyssey as a universal software system for third-party AMR and robotic frameworks, aiming to capture a share of the expanding global robotic software market. Production capacity for AMRs is targeted to expand to 15 units per month by Q3 2025 to meet projected demand and achieve cost efficiencies. The next-generation TransCar 5.0 is expected to launch production in Q4 2025, with its first commercial deployment targeted for Q1 2026, and CE certification expected by Q2 2026. The company also plans to expand its global market presence in security and healthcare facilities management, focusing on the United States, Canada, the United Kingdom, Australia, and GCC countries, by expanding its sales and marketing team and distribution network. Strategic alliances, acquisitions, and investments are also part of the future growth strategy.

Management Comments

• "Our mission is to disrupt, revolutionize, and redefine the global facilities management industry with our AI-enabled AMRs and robotics solutions across security, disinfection, last-mile delivery, and healthcare facilities."
• "Leveraging our core software technologies, robot and machine outdoor autonomy expertise, and AI-enabled AMRs, our products empower customers to enhance productivity, reduce reliance on human capital, and seamlessly integrate automation into their facilities management operations."
• "By addressing labor shortages, rising wages, and labor cost challenges, we aim to empower the entire facilities management industry globally."
• "To drive growth, we are focused on advancing our core software technologies, the commercialization of our latest Autonomous Navigation System (ANS) Version 3, Odyssey, tailored for the AMR and robotics industry, and the expansion of our production capacity."
• "These efforts aim to enable cost-efficient manufacturing and competitive pricing as we develop our next-generation Transcar 5.0 and Camello+ solutions."
• "Additionally, we are actively increasing our global presence in the security and healthcare facilities management industries by expanding our sales and marketing team, strengthening our distribution network, and pursuing strategic alliances, acquisitions, investments, and partnership opportunities."
• "We believe the world is entering a new era where AMRs, robotics and AI are becoming increasingly prevalent in the facilities management."
• "We believe that the shortage of a security, cleaning and delivery workforce will persist as new facilities and buildings continue to be built."
• "We believe these and similar challenges create demand for robotic and AMR substitutes, and we aspire to disrupt the facilities management industry with our AI-enabled AMRs and robotics solutions."
• "We envision that the RaaS model would be attractive to the end-users and accelerates market adoption of our products as it lowers the upfront costs of deployment, shifts capital expenditures to operating expenditures, and provides the operational and technical support with the ability to upgrade any leased product as new technologies emerge."
• "We believe our joint venture with Swisslog Healthcare gives us, through our ownership interest in the Otsaw-Swisslog JV, an opportunity to benefit from Swisslog's TransCar AGV product development expertise, synergies to market our products... and longstanding relationships with many of our target customers in the healthcare industry."
• "We believe the world is entering a new era where robots will become increasingly prevalent in all sectors, and thus we believe the Odyssey will expand our ecosystem coverage by integrating our core software technologies with all relevant players in the robotics industry."
• "Our goal is to expand our production capacity to have at least three months of finished products as the inventory to sell/lease at any given time."
• "We are confident in our ability to take advantage of current market opportunities because hospitals worldwide are expected to upgrade their intralogistics systems to solve labor shortage and productivity challenges that were particularly exposed during the COVID-19 pandemic."
• "We envision to market a multi-layered and integrated AMR solution with multi-fleet coordination abilities to automate critical needs of hospitals, such as disinfection, security, housekeeping, and clinical and non-clinical, low volume and high-volume material intralogistics delivery."
• "Innovation is the key to our success as we remain on the cutting edge of machine learning and robotic autonomy."
• "We believe that the O-R3 is able to stand out from similar products of our competitors due to its capabilities in navigating outdoor environment and in industry applications."
• "Our UV-C disinfection systems use proprietary UV-C LED technology, which we believe delivers safer and more effective disinfection compared to traditional mercury-based systems."
• "We believe that the TransCar AGV is able to stand out from similar products of our competitors because it is multifunctional and is able to handle food, medication, linen and sterile equipment deliveries."
• "We believe that Camello+ is able to stand out from similar products of our competitors because of its modular capabilities, allowing it to be adapted for different use cases, from basic last mile logistics to critical healthcare deliveries."
• "We believe that our AMRs and robotic solutions will augment and enhance human labor. As such, our primary competition will still be traditional modes of human labor."

Industry Context

Otsaw Limited operates within the rapidly expanding global facilities management and robotics industries, which are experiencing significant growth driven by persistent labor shortages, rising wages, and the increasing adoption of automation and AI. The global facility management market was valued at USD 1,277.8 billion in 2023 and is projected to grow at an 8.2% CAGR to USD 2,284.8 billion by 2032. The broader global robotics market is expected to surpass USD 200 billion by 2030 (16.1% CAGR), with the AI robot market alone projected to reach USD 52.6 billion by 2032. Specific segments like healthcare logistics (7.75% CAGR globally), security robotics (14.70% CAGR globally), disinfection robots (19.2% CAGR globally), and autonomous last-mile delivery (23.5% CAGR globally) are all experiencing robust expansion. Otsaw's focus on multi-purpose robots and its RaaS model aligns with the industry trend of seeking cost-effective, efficient, and adaptable solutions to augment human labor and address operational challenges intensified by factors like aging populations and post-COVID hygiene awareness.

Comparison to Industry Standards

• Otsaw differentiates itself from many robotics companies by simultaneously focusing on three key sectors: healthcare, logistics, and security, allowing for versatile solutions.
• For Security Patrol AMRs (O-R3), principal competitors include Kabam Robotics Pte. Ltd., Ninebot Asia Pte. Ltd., SMP Robotics Singapore Pte. Ltd., Knightscope, Inc., and Robotics Assistance Devices, Inc. Otsaw believes its O-R3 stands out due to its outdoor navigation capabilities and industry applications.
• For UV-C disinfection systems, principal competitors include PBA Robotics Pte. Ltd., Sesto Robotics Pte. Ltd., ST Engineering Ltd., and Pudu Technology. Otsaw claims its proprietary UV-C LED technology offers safer and more effective disinfection compared to traditional mercury-based systems, focusing on hospital-grade cleaning.
• For Healthcare Intralogistics AGVs (TransCar), competitors include Oppent S.P.A., Oceaneering International, Inc., Aetheon Inc., Mobile Industrial Robots ApS, DS Automation Ltd., MLR System GmBH, and JBT Corporation. Otsaw believes TransCar AGV stands out due to its multifunctional capabilities in handling food, medication, linen, and sterile equipment deliveries.
• For Last-Mile Delivery AMRs (Camello+), principal competitors include Starship Technologies, Kiwi Campus Inc., and Ottonomy.io. Otsaw believes Camello+ differentiates itself with its modular capabilities, allowing adaptation for various use cases from basic logistics to critical healthcare deliveries.
• Otsaw's primary competition is still traditional human labor and facilities management service providers, and the company aims to demonstrate the cost-efficiency, increased productivity, and reliability of its robots compared to human labor.
• The company's early-mover status in facilities management AMR solutions and established international channels across 20+ countries provide a head-start in customer relationships and institutional knowledge compared to newer entrants.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings or administrative proceedings are currently against the company.
• No awareness of investigations being conducted by a governmental entity into the company.
• No loss contingencies required to be recognized or disclosed as of April 30, 2024, and October 31, 2024.

Related Party Transactions

• The company has outstanding loans from its founder, CEO, and director, Mr. Ling Ting Ming, with an outstanding balance of US$7,231,925 as of the prospectus date, bearing 12% interest per annum.
• A loan from Mr. Goh Way Siong, a shareholder, had an outstanding balance of US$1,994,882 as of the prospectus date, bearing 12% and 6% interest rates.
• Loans from Capital, Credit & Risk Partners Pte Ltd (US$1,713,957 and US$375,560 outstanding as of the prospectus date) and Asian Prosperity Singapore Pte. Ltd. (US$452,207 outstanding as of the prospectus date) are also from related parties (shareholders or entities controlled by directors of shareholders).
• The company has sales and purchases of goods and services with Swisslog Healthcare AG Branch Italy, Swisslog Healthcare AG Branch Netherlands, Swisslog UK, SAS Swisslog France, Activ Technology Group, Swisslog Healthcare GmbH, Swisslog Healthcare AG Branch Germany, and SG Networks Pte Ltd.
• Deferred consideration adjustments related to the acquisition of Swisslog's AGV business resulted in other income of US$259,875 in FY2024 and US$486,468 in FY2023 due to unmet revenue targets.
• Otsaw Logistic Pte Ltd, a loss-making subsidiary, was sold to Mr. Ling Ting Ming for SGD1 on January 31, 2024.
• Mr. Ling Ting Ming acquired an additional 7,957,700 Class A ordinary shares from minority shareholders for US$5,771,110.62 on July 3, 2025, increasing his beneficial ownership.

Stakeholder Impact

• **Shareholders (Existing & New)**: Will experience immediate and substantial dilution (approx. $4.89 or 98% for new investors). Existing shareholders' voting power will be diluted, but the CEO will retain concentrated control. The stock price may be volatile due to small public float and insider holdings. No dividends are expected in the foreseeable future, relying solely on price appreciation.
• **Employees**: The company plans to expand its workforce, particularly in sales, marketing, R&D, and customer service, creating new opportunities. The 2025 Share Incentive Plan aims to incentivize performance and align interests. However, the company's going concern risk could impact job security if funding is not sustained.
• **Customers**: Benefit from advanced AI-enabled robotics solutions that enhance productivity, reduce reliance on human capital, and integrate automation. The RaaS model offers lower upfront costs and comprehensive support. However, supply chain constraints and potential delays in new product launches (e.g., TransCar 5.0 certification) could affect service delivery.
• **Suppliers**: The company's dependence on single/limited source suppliers for key components (e.g., Reis Robotics, semiconductors, lithium-ion cells) creates risk for suppliers if demand fluctuates or if the company faces financial difficulties. Conversely, the company's growth plans could mean increased orders for reliable suppliers.
• **Creditors**: The company has significant outstanding loans, including from related parties, and a working capital deficit. The IPO proceeds will be used to repay some loans, but the company's ability to continue as a going concern and generate positive cash flow is critical for long-term debt repayment.

Next Steps

• Complete the initial public offering and list Class A Ordinary Shares on Nasdaq under the symbol OTSA.
• Utilize net IPO proceeds for strategic acquisitions, joint ventures, expansion of production capacity, market expansion, research and development, working capital, and loan repayment.
• Expand production capacity to 15 units per month by Q3 2025.
• Launch production of TransCar 5.0 in Q4 2025, with first commercial deployment targeted for Q1 2026.
• Complete CE certification for TransCar 5.0 by Q2 2026 and subsequently obtain UL and FCC certifications for the United States.
• Commence development of ANS Version 3, 'Odyssey', in 2026 with a target launch in 2028.
• Continue expanding global market presence in the United States, Canada, the United Kingdom, Australia, and GCC countries.
• Strengthen and expand the sales and marketing team and distribution network globally.
• Pursue strategic alliance, acquisitions, investments, and partnership opportunities.
• Build out the global help desk at Singapore headquarters to support regional centers and distributors.

Key Dates

Recommendation

Keywords

Autonomous Mobile Robots, Robotics Solutions, Facilities Management, AI-enabled, Security Robots, Disinfection Systems, Last-Mile Delivery, Healthcare Logistics, AGVs, O-R3, Camello+, TransCar, UV-C LED, 3D SLAM, Sensor Fusion, Machine Perception, Fleet Management, Singapore, Nasdaq IPO, Emerging Growth Company, Foreign Private Issuer, Controlled Company, Supply Chain, Intellectual Property, Share Incentive Plan, Going Concern, Net Loss, Working Capital Deficit, International Expansion, Swisslog Healthcare Joint Venture